Analytical Data
-
Gene name
Carbonic Anhydrase 9
- Application
-
Alternative Names
CA-IX; CAIX; MN; pMW1; P54/58N; Carbonic Dehydratase; Renal cell carcinoma-associated antigen G250; RCC-Associated Protein G250; Carbonate dehydratase IX
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q16790
-
Expression Region
Pro59~Asp414
-
Molecular Weight
45kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Carbonic Anhydrase 9 (CA9) is a metalloenzyme that plays a crucial role in regulating pH and bicarbonate levels within cells, particularly in hypoxic tumor microenvironments. It catalyzes the reversible hydration of carbon dioxide to bicarbonate and protons, which is vital for various physiological processes, including respiration, acid-base balance, and metabolic function. CA9 is notably overexpressed in several malignancies, including renal cell carcinoma, glioblastoma, and breast cancer, making it a significant biomarker for tumor diagnosis and prognosis. Research has increasingly focused on the development of CA9-targeted therapies and diagnostic tools, as its unique expression pattern in tumors versus normal tissues presents an opportunity for selective cancer treatment. Recombinant proteins of CA9 are utilized for investigating its enzymatic properties, understanding its role in tumor biology, and exploring its potential as a therapeutic target. Advanced techniques in molecular biology and protein engineering have enabled the production of CA9 recombinant proteins for structural studies and drug screening, facilitating the discovery of small molecules that can inhibit its activity. Thus, the study of recombinant CA9 not only enhances our understanding of its biological functions but also propels the development of innovative cancer treatments and diagnostic modalities, pointing towards a promising avenue for future cancer research and precision medicine.
